Andrew Saunders | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Andrew Saunders is active.

Explore More

Publication

Featured researches published by Andrew Saunders.

Blood | 2013

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory and High Risk Chronic Lymphocytic Leukaemia (CLL)

Lionel Karlin; Simon Rule; Nimish Shah; Franck Morschhauser; Louis Terriou; Martin J. S. Dyer; BMedSci Claire Hutchinson; Chris Fegan; Guillaume Cartron; Tomasz Knurowski; Andrew Saunders; James G Wright; Hideyuki Honda; Andrew Mazur; Toshio Yoshizawa; Kazuhito Kawabata; Joseph Birkett

Cancer Chemotherapy and Pharmacology | 2013

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study.

Eric Van Den Neste; Bruno Cazin; Ann Janssens; Eva González-Barca; María José Terol; Vincent Levy; Jaime Pérez de Oteyza; Pierre Zachee; Andrew Saunders; Mercè de Frias; Clara Campàs

Blood | 2013

A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma

Nimish Shah; Gilles Salles; Lionel Karlin; Franck Morschhauser; Louis Terriou; Martin J. S. Dyer; Chris Fegan; Guillaume Cartron; Tomasz Knurowski; James G Wright; Andrew Saunders; Hideyuki Honda; Andrew Mazur; Toshio Yoshizawa; Kazuhito Kawabata; Joseph Birkett

Blood | 2006

Effectiveness of Clofarabine in Elderly AML Patients with Adverse Cytogenetics Unfit for Intensive Chemotherapy.

Alan Kenneth Burnett; Michele Baccarani; Peter Johnson; John A. Liu Yin; Andrew Saunders; Nigel H. Russell; Robert Kerrin Hills

Blood | 2014

A Phase II Open-Label, Multi-Center Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab (KW-0761) in Patients with Previously Treated Peripheral T-Cell Lymphoma(PTCL)

Pier Luigi Zinzani; Bertrand Coiffier; John Radford; Dolores Caballero; Paul Fields; Martine E.D. Chamuleau; Francesco d'Amore; Corinne Haioun; Catherine Thieblemont; Eva González Barca; Carlos Grande García; Peter Johnson; Gustaaf W. van Imhoff; Andrew Saunders; Karen Dwyer; Franck Morschhauser

Journal of Clinical Oncology | 2017

Anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab) or investigator’s choice of chemotherapy in subjects with relapsed or refractory adult T-cell leukemia-lymphoma (ATL).

Adrienne Phillips; Paul Fields; Olivier Hermine; Graham R. Taylor; Maria Delioukina; Steven M. Horwitz; Juan Carlos Ramos; Jean CÃƒÂ´me Meniane; Stefan K. Barta; Karen Dwyer; Michael R. Kurman; Andrew Saunders; Dmitri O. Grebennik; Kevin C. Conlon

Journal of Clinical Oncology | 2017

LTX-315, an oncolytic peptide, to convert immunogenically ‘cold' tumors to ‘hot' in patients with advanced or metastatic tumours: Results from an ongoing phase I study.

James Spicer; Jean-François Baurain; Ahmad Awada; Rebecca Kristeleit; Dag Erik Jøssang; Aurelien Marabelle; Delphine Loirat; Hedda Wold; Berit Nicolaisen; Øystein Rekdal; Wenche Marie Olsen; Andrew Saunders; Paal Brunsvig

Journal of Clinical Oncology | 2017

The Bruton’s tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.

Martin J. S. Dyer; Simon Rule; Nimish Shah; Gilles Salles; Lionel Karlin; Franck Morschhauser; Louis Terriou; Chris Fegan; Andrew J. Davison; Guillaume Cartron; Andrew Saunders; Hideyuki Honda; John Sharpe; Toshio Yoshizawa; Tomoko Yasuhiro; Kazuhito Kawabata; Hiroshi Awata; Joseph Birkett

Blood | 2010

Acadesine for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase I/II Study

Eric Van Den Neste; Bruno Cazin; Ann Janssens; Eva González-Barca; María José Terol; Vincent Levy; Jaime Pérez de Oteyza; Pierre Zachee; Andrew Saunders; Mercè de Frias; Clara Campàs

Blood | 2009